Q1 FY2027 · ended Aug 31, 2026 · Revenue $1.26M, -8.3% YoY · Filed Oct 15, 2026
Biomerica, Inc. (BMRA) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In Q1 of fiscal 2027, the quarter ended Aug 31, 2026, it reported revenue of $1.3 million and a net loss of $1.2 million. As of Aug 31, 2026 it held $2.7 million in cash and investments and $1.8 million in total debt.
Revenue
$1.26M
-8.3% vs year-ago quarter
Net income
$-1.23M
-61700.0% vs year-ago quarter
Operating cash flow
$-802,000
-199.3% vs year-ago quarter
Free cash flow
—
EPS
$-0.37
Dividend per share
None
Shares outstanding
4.60M
+60.2% vs year-ago quarter
Net cash
$907,000
Q1 FY2027
Operating margin
-125.1%
TTM
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- BMRA (Nasdaq)
- Fiscal year ends
- May 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 73290
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Aug 31, 2026 |
Q4 FY2026 May 31, 2026 |
Q3 FY2026 Feb 28, 2026 |
Q2 FY2026 Nov 30, 2025 |
Q1 FY2026 Aug 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.3M | $875,000 | $987,000 | $1.2M | $1.4M |
| Operating income | -$1.2M | -$1.5M | -$1.3M | -$1.4M | -$1.1M |
| Net income | -$1.2M | -$1.1M | -$1.3M | -$1.3M | $2,000 |
| Diluted EPS | -$0.37 | -$0.37 | -$0.44 | -$0.45 | $0.00 |
| Operating cash flow | -$802,000 | -$912,000 | -$1.2M | -$991,000 | -$268,000 |
| Total assets | $8.1M | $6.8M | $4.9M | $6.0M | $6.9M |
| Total liabilities | $4.4M | $4.1M | $1.6M | $1.6M | $1.7M |
| Stockholders' equity | $3.6M | $2.6M | $3.3M | $4.4M | $5.2M |
| Cash and investments | $2.7M | $1.3M | $1.3M | $2.5M | $3.1M |
| Total debt | $1.8M | $1.9M | $193,000 | $284,000 | $373,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 15, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 15, 2026 | Oct 9, 2026 |
| 10-K/A | Amended annual report | Sep 28, 2026 | May 31, 2026 |
| 10-K | Annual report | Aug 31, 2026 | May 31, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 26, 2026 | Aug 20, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jun 4, 2026 | May 29, 2026 |
All 605 Biomerica, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.